secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001411685-24-000042
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen enrolls first subject in PALISADE-4 Phase 3 trial of fasedienol for SAD
--------------------------------------------------------------------------------

- First subject enrolled in PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder (SAD).
- Fasedienol is an investigational neuroactive pherine candidate in U.S. registration-directed Phase 3 development.
- Over 30 million Americans suffer from SAD; no FDA-approved acute treatments currently available.
- Fasedienol targets nose-to-brain neural circuits to reduce fear and anxiety associated with SAD.
- CEO Shawn Singh confirmed the milestone was achieved as planned in the registration-directed program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000042/0001411685-24-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000042/vtgn-20240923.htm
  HTML page:      https://secwatch.observer/filing/0001411685-24-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer